Cargando…

Outcomes in Post Lung Transplant Patients Diagnosed with COVID 19

PURPOSE: The manifestations and complications of SARS-CoV-2 infection in solid organ transplant are poorly known. Lung Transplant group is an immunocompromised group with a shock organ of COVID-19. For this, we analyze the possible risk factors associated with an unfavorable outcome METHODS: Retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Pêgo-Fernandes, P., Reis, F. Pola Dos, Santos, S., Fernandes, L.M., Abdalla, L.G., Aguiar, I.T., Campos, S.V., de Camargo, P. L. Bueno, Costa, A.N., Carraro, R.M., Pires, J.P., Teixeira, R.O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988623/
http://dx.doi.org/10.1016/j.healun.2022.01.1555
Descripción
Sumario:PURPOSE: The manifestations and complications of SARS-CoV-2 infection in solid organ transplant are poorly known. Lung Transplant group is an immunocompromised group with a shock organ of COVID-19. For this, we analyze the possible risk factors associated with an unfavorable outcome METHODS: Retrospective study between the period march 2020 until june 2021. We analysed the database of Lung Transplant and medical records. It included all patients with a confirmed diagnosis of COVID-19 in our cohort with RT-PCR SARS-COV-2 or rapid test and chest computed tomography compatible. We analyzed demographic features and outcomes: sex; type of transplant (unilateral or bilateral); presence of chronic graft dysfunction; transplant time; confirmed prior rejections; history of SAH and/or DM; nosocomial transmission infection; report of fever and/or dyspnea; need for hospitalization and/or ICU; use of an O2 nasal catheter and/or mechanical ventilation; need of dyalisis; associated bronchopneumonia (confirmed by culture); and previous use of 2 or more immunosuppressants. Statistical analysis was performed and multivariate analysis RESULTS: In our cohort, we had 213 patients in follow-up (March 2020) and during this period 29 (13.6%) patients with COVID-19 were evaluated. These 23 with diagnosis and supervised treatment in our service and 6 patients in external follow-up of the infectious condition. Overall death was 31% (9).The mean age of patients is 46 years (±15.66), being 51.8% male and 48.2% female. A multivariate analysis, only dialysis (HR 9.186 - CI 1.804-46.758 - p=0.008) and bronchopneumonia (HR 7.554 - CI 1.510-37.790 - p=0.014) are associated with a negative outcome. CONCLUSION: The lethality is high in this group of patients. Our data was shown that dialysis and bronchopneumonia are associated with a higher risk of death in this group of patients infected with COVID-19. We emphasize that the limitation of this work is mainly due to the small sample analyzed. We suggest more studies are necessary.